Atypical haemolytic uraemic syndrome (aHUS) - eculizumab: evaluation consultation
Atypical haemolytic uraemic syndrome (aHUS) - eculizumab: evaluation report
01 - Pre-Meeting Briefing prepared by NICE
02 - Submission by the technology manufacturer - Alexion
03 - NICE request to the manufacturer for clarification on their submission
04 - Manufacturer clarification response
05 - Consultee submission - aHUS UK Part 1
06 - Consultee submission - aHUS UK Part 2
07 - Consultee submission - Kidney Research UK
08 - Consultee submission - aHUS Action Part 1 - Professional Statement
09 - Consultee submission - aHUS Action part 2 - diagnostic check list
10 - Consultee submission - aHUS Action Part 3 -Transplant protocol
11 - Consultee submission - Royal College of Physicians
12 - Consultee submission - NHS England
13 - NHSe Clinical Commissioning Policy Statement
14 - Clinical expert personal perspective - Gilbert
15 - Clinical expert personal perspective - Goodship
16 - Patient expert personal perspective - Lilley
17 - Clinical expert personal perspective - Scully
18 - Patient expert personal perspective - Woodward
19 - Evidence Review Group Report prepared by ScHARR
20 - Manufacturer factual accuracy check of Evidence Review Group report
Please be advised that the format of evaluation reports shared on the NICE website has recently changed, for ease of user navigation between individual documents contained in the report.
It is a requirement of the new (PDF portfolio) format that Adobe Reader is used to view the document. Please follow the link at the bottom of this page to download Adobe Reader if required.
If you have any feedback on the new format please contact the Project Manager for this evaluation.
*Users of Google chrome should click the link below and then click the small PDF icon in the far right of the address bar to successfully access this document *
Atypical haemolytic uraemic syndrome (aHUS) - eculizumab: evaluation report 27 February 2014 (6.03 Mb 29 mins @ 28.8Kbps) |